BECN1 and neoplasm: Furthermore, autophagy inhibition, through the use of pharmacological inhibitors (3-Methyladenine, Hydroxychloroquine) or shRNA targeting BECN1 or ATG5 resulted in a significant improvement of the anti-myeloma activity of the chemotherapeutic treatment, both in vitro (increased apoptosis cell death) and in vivo (xenografted tumour growth prevention through apoptosis induction).